Phaseline

Companies › Plexium

Plexium: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PLX-61639
SMARCA2 degrader
SMARCA2Phase 1Esophageal Squamous Cell CarcinomaDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07284186PLX-61639Phase 1Esophageal Squamous Cell CarcinomaOncologyDec 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

SMARCA2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.